| 3.52 -0.23 (-6.13%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.19 |
1-year : | 5.92 |
| Resists | First : | 4.45 |
Second : | 5.07 |
| Pivot price | 4.01 |
|||
| Supports | First : | 3.45 |
Second : | 2.87 |
| MAs | MA(5) : | 3.73 |
MA(20) : | 4.13 |
| MA(100) : | 3.37  |
MA(250) : | 2.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.1 |
D(3) : | 9.3 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 5.07 | Low : | 1.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ STIM ] has closed above bottom band by 1.6%. Bollinger Bands are 3.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.7 - 3.72 | 3.72 - 3.74 |
| Low: | 3.39 - 3.42 | 3.42 - 3.44 |
| Close: | 3.48 - 3.52 | 3.52 - 3.56 |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Mon, 01 Apr 2024
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression - Yahoo Finance
Thu, 07 Mar 2024
Neuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023 - Yahoo Finance
Thu, 07 Mar 2024
Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 06 Mar 2024
Neuronetics Inc Boosts Executive Compensation for Top Leaders - TipRanks.com - TipRanks
Tue, 05 Mar 2024
Neuronetics Inc Shares New Investor Insights Online - TipRanks.com - TipRanks
Tue, 05 Mar 2024
Neuronetics: Q4 Earnings Snapshot - Quartz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 30 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 65.2 (%) |
| Shares Short | 95 (K) |
| Shares Short P.Month | 152 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.16 |
| Profit Margin | -42.4 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | -15.4 % |
| Return on Equity (ttm) | -66.2 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.38 |
| EBITDA (p.s.) | -0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -3.36 |
| PEG Ratio | 0 |
| Price to Book value | 3 |
| Price to Sales | 1.47 |
| Price to Cash Flow | -3.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|